Stage 1: The Proof — 2026 to 2031

Build clinical prototype (Q2-26 to Q2-27)

Clinical development and manufacturing (Q1-27 to Q4-27)

Design Verification & Validation (Q3-27 to Q4-28)

EFS readiness (Q1-26 to Q2-28)

Early Feasibility Study in recurrent GBM (Q1-29 to Q4-31)

Raising $6M — $2M already secured

Stage 2: The Precedent — 2031 to 2033

Pivotal trial in newly-diagnosed GBM

Development of Stasis v2

Revenue scaling from $50M to $500M

Stage 3: The Platform — 2033 onwards

Leverage Stasis against other neurological conditions

High-grade CNS neoplasms, low-grade gliomas, epilepsy, brain injury

Thermal neuromodulation platform — global expansion